NRx Pharmaceuticals, Inc. (NRXPW) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
1201 Orange Street
Wilmington, DE 19801
United States of America (the)
Phone
484 254 6134
Website
Sector
Healthcare
Industry
Biotechnology
Employees
10
First IPO Date
December 01, 2017
| Name | Title | Pay | Year Born |
| Jonathan C. Javitt | Co-Founder, Chairman & CEO | 846,774 | 1957 |
| Dennis K. McBride | Chief Strategy Officer & Director | 38,462 | 1955 |
| Riccardo Panicucci | Chief Manufacturing & Technology Officer | 240,000 | 1962 |
| Michael S. Abrams | CFO & Treasurer | 363,083 | 1970 |
| Glenn Tyson | Chief Commercial Officer | 0 | N/A |
| Joseph Casper | Chief Operating Officer | 0 | 1951 |
| Joshua C. Brown | Chief Medical Innovation Officer | 0 | N/A |
| Suzanne Messere | Investor Relations | 0 | N/A |
| Hervé Perron | Chief Scientist | 0 | 1959 |
| Philip T. Lavin | Chief Methodologist | 0 | 1947 |
NRx Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical firm, concentrating on the development of novel therapies for central nervous system ailments and life-threatening lung conditions. Its portfolio includes ZYESAMI, an investigational medicine that has progressed through Phase IIb/III clinical trials for severe respiratory distress linked to COVID-19. Additionally, the company is advancing NRX-100 and NRX-101, orally administered treatments engineered to address bipolar depression in individuals exhibiting both acute and sub-acute suicidal ideation and actions. This Delaware-based company, located in Wilmington, was established in 2015.